MX2022014133A - Tratamiento para cancer de mama usando tratamientos conjuntos que comprenden gdc-9545 y un inhibidor de cdk4/6. - Google Patents

Tratamiento para cancer de mama usando tratamientos conjuntos que comprenden gdc-9545 y un inhibidor de cdk4/6.

Info

Publication number
MX2022014133A
MX2022014133A MX2022014133A MX2022014133A MX2022014133A MX 2022014133 A MX2022014133 A MX 2022014133A MX 2022014133 A MX2022014133 A MX 2022014133A MX 2022014133 A MX2022014133 A MX 2022014133A MX 2022014133 A MX2022014133 A MX 2022014133A
Authority
MX
Mexico
Prior art keywords
breast cancer
gdc
cdk4
inhibitor
treatment
Prior art date
Application number
MX2022014133A
Other languages
English (en)
Spanish (es)
Inventor
Marjorie C Green
Sandra Milan
LAUCHLE Jennifer O''hara
Melanie Carol Smitt
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2022014133A publication Critical patent/MX2022014133A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2022014133A 2020-05-12 2021-05-10 Tratamiento para cancer de mama usando tratamientos conjuntos que comprenden gdc-9545 y un inhibidor de cdk4/6. MX2022014133A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063023501P 2020-05-12 2020-05-12
PCT/US2021/031491 WO2021231250A1 (en) 2020-05-12 2021-05-10 Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor

Publications (1)

Publication Number Publication Date
MX2022014133A true MX2022014133A (es) 2022-11-30

Family

ID=76250442

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014133A MX2022014133A (es) 2020-05-12 2021-05-10 Tratamiento para cancer de mama usando tratamientos conjuntos que comprenden gdc-9545 y un inhibidor de cdk4/6.

Country Status (11)

Country Link
US (2) US11918561B2 (cg-RX-API-DMAC7.html)
EP (1) EP4149476A1 (cg-RX-API-DMAC7.html)
JP (3) JP2023500558A (cg-RX-API-DMAC7.html)
KR (1) KR20230009390A (cg-RX-API-DMAC7.html)
CN (2) CN120324434A (cg-RX-API-DMAC7.html)
AU (2) AU2021272100B2 (cg-RX-API-DMAC7.html)
CA (1) CA3182018A1 (cg-RX-API-DMAC7.html)
IL (1) IL298071A (cg-RX-API-DMAC7.html)
MX (1) MX2022014133A (cg-RX-API-DMAC7.html)
TW (1) TWI800827B (cg-RX-API-DMAC7.html)
WO (1) WO2021231250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7846700B2 (ja) * 2021-02-16 2026-04-15 ジェネンテック, インコーポレイテッド Gdc-9545とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療
TW202400230A (zh) * 2022-03-14 2024-01-01 美商建南德克公司 乳癌的組合療法
CN121337802B (zh) * 2025-10-23 2026-04-14 安徽益普克医药科技发展有限公司 一种雌激素降解剂衍生物及其制备方法与用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4772247A2 (en) * 2013-08-14 2026-07-08 Novartis AG Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
KR102358935B1 (ko) * 2014-02-12 2022-02-04 가부시키가이샤 한도오따이 에네루기 켄큐쇼 전자 기기
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
MX384605B (es) 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
WO2017160990A1 (en) 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
LT3810283T (lt) * 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
AU2019321588C1 (en) 2018-08-17 2026-05-14 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
JP7826068B2 (ja) * 2022-03-11 2026-03-09 本田技研工業株式会社 パワーユニット、及びパワーユニットを搭載した作業機

Also Published As

Publication number Publication date
US20240173306A1 (en) 2024-05-30
US11918561B2 (en) 2024-03-05
AU2021272100B2 (en) 2024-09-12
EP4149476A1 (en) 2023-03-22
AU2024202832B2 (en) 2026-04-30
JP2023500558A (ja) 2023-01-10
KR20230009390A (ko) 2023-01-17
US12303495B2 (en) 2025-05-20
CN120324434A (zh) 2025-07-18
IL298071A (en) 2023-01-01
AU2021272100A1 (en) 2022-11-17
US20210353601A1 (en) 2021-11-18
CN115551513B (zh) 2025-05-02
AU2024202832A1 (en) 2024-05-23
TWI800827B (zh) 2023-05-01
CN115551513A (zh) 2022-12-30
CA3182018A1 (en) 2021-11-18
WO2021231250A1 (en) 2021-11-18
JP2024102045A (ja) 2024-07-30
TW202203913A (zh) 2022-02-01
JP2023175688A (ja) 2023-12-12

Similar Documents

Publication Publication Date Title
CL2025002208A1 (es) Inhibidores de kif18a para el tratamiento de enfermedades neoplásicas
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
DOP2010000141A (es) Tratamiento de cancer de mama con un inhibidor de parp solo o en combinacion con agentes anti-tumorales
MX2019011221A (es) Terapia de combinacion para el tratamiento o prevencion de tumores.
CL2018000943A1 (es) Terapia de combinación para tratar tumores malignos
MX381582B (es) Terapia de combinacion para el tratamiento de neoplasias malignas.
MX2018004587A (es) Terapia de combinacion para tratar tumores malignos.
BR112022008295A2 (pt) Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer
MX2018004595A (es) Terapia combinada para el tratamiento de neoplasias malignas.
MX390121B (es) Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas.
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
BR112019019261A2 (pt) Terapias de combinação para o tratamento de câncer de mama
MX2024006678A (es) Inhibidor de cdk4 para el tratamiento del cancer.
MX2021015403A (es) Terapia de combinacion que comprende un conjugado de anticuerpo-farmaco anti-cd19 y un inhibidor de pi3k o un agente secundario.
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
NI201500055A (es) Tratamiento de cáncer de próstata con inhibidores de quinasa tor
MX2024012368A (es) Terapia combinada para el tratamiento del cancer
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres
NI202000052A (es) Terapia de combinación para tratar o prevenir el cáncer
MX386249B (es) Terapia tusc2 para usarse en el tratamiento de cáncer.
CL2024001678A1 (es) Tratamiento del cáncer con un inhibidor de la cinasa fgfr
MX2021009182A (es) Antiandrogenos para el tratamiento de cancer de prostata metastasico sensible a la castracion.
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
CR20240348A (es) Compuestos y su uso en el tratamiento del cáncer